top of page

Radium-226

Image by Bosco Shots

Why Radium-226?

Radium-226 is the essential "master feedstock" for modern nuclear medicine. While it has a long history in early radiotherapy, its primary value today lies in its role as the critical precursor for Actinium-225.

Because global stockpiles of high-purity Ra-226 are limited, securing this material is the single most important step in ensuring a reliable supply of next-generation cancer treatments.

Technical Snapshot

Isotope: Radium-226 (Ra-226)

Decay Mode: Alpha and Gamma emission

Half-life: ~1,600 years

Parent Source: Naturally occurring in the Uranium-238 decay chain

Primary Use: Target material for Ac -225 production via photonuclear reaction

_edited.jpg

Its Role: The Foundation of Alpha Therapy

In the Southern Cross Medical Radioisotopes (SCMR) production model, Ra-226 serves as the target material. When placed inside one of our high-energy electron accelerators (rhodotron), it undergoes a photonuclear reaction to become Ra-225, which then decays into the high-potency Ac-225.

By mastering this conversion, SCMR transforms a legacy isotope into the most sought-after therapeutic agent in oncology.

The SCMR Advantage: Upstream Control

Most radioisotope producers rely on dwindling global stockpiles of radium. SCMR is taking a different approach by establishing a vertically integrated supply chain:
 

  • Direct Extraction: We are developing capabilities to extract Ra-226 directly from uranium ore (pitchblende).
     

  • Sovereign Supply: By utilising Australian resources, we remove the risks associated with international logistics and geopolitical disruptions.
     

  • Purity Standards: Our extraction and purification processes ensure that the Ra-226 used in our accelerators meets the rigorous specific-activity requirements for medical-grade production.

Transforming a Legacy into a Future

Historically viewed as a byproduct of the uranium industry, Ra-226 is being reclaimed by SCMR as a strategic asset. Our focus on securing and processing this upstream resource ensures that our facility can scale production to meet the exponential growth of the global Targeted Alpha Therapy (TAT) market.

bottom of page